This week’s Newsmaker is Yukti Choudhury of HistoIndex, discussing FibroSIGHT, the company’s new diagnostic for use in clinical practices.
A diverse group of MASLD/MASH stakeholders joins Jörn Schattenberg and Roger Green to discuss The Liver Meeting 2024 about key breakthroughs, explore emerging research on new therapies, and reflect on collaborative efforts that advance patient care and outcomes in the field.
Maru Rinella, corresponding author for the recent expert panel recommendations on resmetirom, joins the Surfers to discuss key points of the recommendations and the rationale behind them.
In the second half of Roger Green’s interview with Global Liver Institute Vice President, Liver Programs Jeff McIntyre, Jeff discusses the implications of his key EASL Congress takeaways for GLI and other patient advocacy groups.
Global Liver Institute Vice President of Liver Programs Jeff McIntyre joins Roger Green to discuss what he considers key takeaways for GLI from EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key implications for his business from what he learned at EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key takeaways for his business from EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean and Global LIver Institute Vice President of Liver Programs Jeff McIntyre join Roger Green for 1:1 interviews exploring their key takeaways and strategic shifts resulting from the EASL Congress 2024, followed by a review of answers to a previous Question of the Week.
In this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss some of the guidelines’ key goals and issues surrounding the screening, diagnosis and management of MASLD patients.
Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
